Cadrenal Therapeutics is a biopharmaceutical company developing a late-stage novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism, more commonly referred to as blood clots, of cardiac origin in patients with end-stage renal disease and atrial fibrillation (ESRD + AFib).